TM9SF4

Across TCGA pan-cancer cohorts, TM9SF4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TM9SF4 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TM9SF4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TM9SF4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, COAD, and ESCA are the cancer types where TM9SF4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	III,IV	0.003	0.633	<.001	12	view →
COAD	OS	Median	All	0.171	0.615	.007	8	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
LUSC	DFS	Median	II,III,IV	0.135	0.663	.015	3	view →
UCEC	DFS	Median	II,III,IV	0.915	0.439	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TM9SF4–STAD (OS)

Open the STAD breakdown →